pharmaphorum October 18, 2022
One of the first actions by GSK’s recently appointed chief scientific officer, Tony Wood, has been to expand a partnership with Tempus aimed at improving the big pharma’s R&D productivity, starting with its cancer pipeline.
US-based Tempus has built a precision medicine platform – powered by artificial intelligence and machine learning – that sifts through a large library of anonymised patient data, including results of clinical, molecular, and genomic testing. Its aim is for patients to benefit from the treatment of others who came before, by providing data tools to drug developers and healthcare professionals.
GSK is the latest pharma group to tap into that resource, with the aim of teasing out new drug targets, improving the design of its...
Today's Sponsors
Today's Sponsor